Top-line three-source view and TSO verification conclusion:
Source 1 (Nature): Confirms that the ΨDNA-guided CRISPR-Cas12a system can achieve “precise and efficient depletion of endogenous RNA transcripts” and can do so individually or in multiplex.
Source 2 (GEN): Emphasizes that the research team designed a “DNA guide” that “mimics the crRNA scaffold in reverse orientation,” enabling AsCas12a and Cas12i1 to bind RNA and trigger strong single-stranded DNA trans-cleavage.
Source 3 (News-Medical): Provides specific reduction data, stating that ΨDNA guides reduced target RNA levels by 50–70% in standard experiments and by 80–95% in optimized cellular systems.
TSO verification conclusion: The three sources mutually confirm the core event — the same study on ΨDNA/DNA guide reprogramming of Cas12a/Cas12i1 for RNA targeting and its May 2026 reporting. The shared, confirmable facts are the “DNA-guided/ΨDNA-guided Cas12 RNA targeting” direction and its ability to reduce or deplete RNA. Specific mechanistic wording and quantitative results differ by source and must be labeled separately rather than conflated.
Confirmed shared facts:
The research topic is the same across the sources: a DNA-guided CRISPR-Cas12 RNA targeting platform.
The target is RNA, not solely DNA editing.
The core system involves Cas12a, and GEN plus the event summary also mention Cas12i1.
The functional direction is RNA detection, knockdown/reduction, and multiplex targeting; Nature explicitly mentions both “individually” and “multiplexed” removal of endogenous RNA transcripts.
The result direction is consistent: the system can effectively reduce target RNA levels or remove endogenous RNA transcripts.
Main differences:
Quantitative data appears only in Source 3: reductions of 50–70% and 80–95%. Sources 1 and 2 do not provide these specific values. It cannot be confirmed from the given sources whether these numbers are from the paper text or from media summaries.
Mechanistic details appear only in Source 2: phrases such as “mimics the crRNA scaffold in reverse orientation” and “trigger strong single-stranded DNA trans-cleavage” are not mentioned by Source 1 and are absent from Source 3.
Different emphasis:
Nature focuses on the paper’s conclusion and system performance;
GEN focuses on the molecular design logic and the mechanism by which AsCas12a/Cas12i1 bind RNA;
News-Medical focuses on the magnitude of the experimental effect.
Application scope: Source 1 confirms at least multiplex and depletion capability in RNA detection, knockdown, and multiplex targeting. Sources 2 and 3 do not fully cover all application scenarios. For “detection,” the given sources do not allow independent confirmation of specific experimental details.
Background and analysis:
Taken together, the three sources show that the key significance of this study is extending the Cas12 system from its traditional DNA-targeting context into an RNA-targeting context. However, this “extension” wording appears only in Source 3’s headline; the precise academic boundaries and mechanistic details should still be based on the Nature paper itself.
The main strictly confirmable point is not the promotional framing, but that the ΨDNA/DNA guide can be used to reprogram Cas12a/Cas12i1 and achieve effective reduction of endogenous RNA transcripts in cellular environments, while supporting multiplex targeting.
For externally discussed functions such as “editing,” “detection,” and “knockdown,” the provided sources only confirm relevance to RNA detection, knockdown, and multiplex targeting. Whether there are broader or more efficient applications is not mentioned and cannot be confirmed.
Because only News-Medical provides explicit percentages and the other two sources do not provide comparable figures, those reduction numbers should not be treated as facts jointly confirmed by all three sources.
Three-source summary:
Source 1 (Nature): conclusion-oriented, confirming that ΨDNA-guided Cas12a can efficiently and precisely clear endogenous RNA and support both single-target and multiplex targeting.
Source 2 (GEN): design-oriented, highlighting the reverse mimicry of the DNA guide relative to the crRNA scaffold and the RNA binding/trans-cleavage mechanism of AsCas12a/Cas12i1.
Source 3 (News-Medical): effect-oriented, reporting the range of target RNA reduction and describing the system as expanding the functional boundaries of Cas12.
Conclusion:
Taken together, the three sources confirm the same study and its May 2026 report: ΨDNA/DNA guide reprogramming of Cas12a/Cas12i1 for RNA targeting. The confirmed facts center on the ability to target RNA, reduce endogenous RNA, and support multiplex targeting. The differences lie mainly in mechanistic explanation and effect-size numbers. Any content not explicitly present in the sources should be treated as “not mentioned by the source” or “cannot be confirmed from the given sources.”